Effectiveness of the live attenuated and the inactivated influenza vaccine in two-year-olds - a nationwide cohort study Finland, influenza season 2015/16.
Although widely recommended, influenza vaccination of children is part of the national vaccination programme only in few countries. In addition to Canada and the United States (US), in Europe Finland and the United Kingdom have introduced live attenuated influenza vaccine (LAIV) for healthy children in their programmes. On 22 June 2016, the US Advisory Committee on Immunizations Practices, voted against further use of LAIV due to no observed vaccine effectiveness (VE) over three consecutive influenza seasons (2013/14 to 2015/16). We summarise the results of a nationwide, register-based cohort study (N=55,258 of whom 8,086 received LAIV and 4,297 TIV); all outcome (laboratory-confirmed influenza), exposure (vaccination) and confounding variable data were retrieved from four computerised national health registers, which were linked via a unique personal identity code assigned to all permanent Finnish residents regardless of nationality. Our study provides evidence of moderate effectiveness against any laboratory-confirmed influenza of the quadrivalent LAIV vaccine (VE: 51%; 95% confidence interval (CI): 28-66%) as well as the inactivated trivalent vaccine (VE: 61%; 95% CI: 31-78%) among two-year-olds during the influenza season 2015/16 in Finland. Based on these data, Finland will continue using LAIV for young children in its National Immunisation Programme this coming influenza season.
Vaccine Programme Unit, Department of Health Protection, National Institute for Health and Welfare, Finland.
Hanna
H
Nohynek
Ulrike
U
Baum
Ritva
R
Syrjänen
Niina
N
Ikonen
Jonas
J
Sundman
Jukka
J
Jokinen
D002675:Child, Preschool; D015331:Cohort Studies; D005260:Female; D005387:Finland / Q000453:epidemiology; D005500:Follow-Up Studies; D006801:Humans; D017589:Immunization Programs; D053118:Influenza A Virus, H1N1 Subtype / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology; D007251:Influenza, Human / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control*; D007753:Laboratories; D008297:Male; D017063:Outcome Assessment, Health Care; D016133:Polymerase Chain Reaction; D012621:Seasons; D018571:Sentinel Surveillance; D014611:Vaccination / Q000706:statistics & numerical data; D014613:Vaccines, Attenuated / Q000008:administration & dosage* / Q000276:immunology; D015164:Vaccines, Inactivated / Q000008:administration & dosage* / Q000276:immunology
D007252:Influenza Vaccines; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated
immunisation; influenza; live attenuated vaccine, inactivated vaccine, children; vaccines
Vaccine. 2006 Jun 5;24(23):4934-41
16678945
Epidemiol Infect. 2016 Apr;144(6):1267-77
26482721
Clin Ther. 2009 Oct;31(10):2140-7
19922885
Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):14001-6
10570188
Euro Surveill. 2016 Sep 22;21(38):
27684603
Euro Surveill. 2016;21(13):null
27074651
Euro Surveill. 2014 Apr 24;19(16):20780
24786262
Scand J Public Health. 2012 Aug;40(6):505-15
22899561
Int Stat Rev. 2010 Apr;78(1):40-64
21743766